<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31786">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912118</url>
  </required_header>
  <id_info>
    <org_study_id>NL43511.058.13</org_study_id>
    <nct_id>NCT01912118</nct_id>
  </id_info>
  <brief_title>The Medasense Study</brief_title>
  <official_title>Measurement of Nociceptive Index During General Anesthesia in ASA 1‐3 Patients Undergoing Elective Surgery Using the Nociception Level (NoL) Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medasense Biometrics Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: Ministry of Health, Welfare and Sport</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite various efforts there is still the need for adequate monitoring of pain and
      nociception during anesthesia. In a previous protocol the investigators measured pain
      responses during anesthesia based on single end‐points, eg heart rate,blood pressure and
      pulse transit time. None of these parameters provided sufficient information regarding
      nociception. The investigators therefore want to further investigate this matter using a
      composite parameter, the Nociception Level or NoL. The NoL is a novel index that measures
      the magnitude of the autonomic response to painful stimuli. The NoL combines information
      from several physiological parameters, which represent different autonomic pathways. The
      multi‐parameter approach empowered with state‐of‐the‐art signal processing and machine
      learning techniques. In the current study the investigators will measure the NoL in ASA 1‐3
      patients undergoing elective surgery under general anesthesia. The investigators will
      measure NoL responses and the occurrence of patient movement upon the administration of a
      painful stimulus: Introduction of the laryngoscope, Insertion of the endotracheal tube,
      Insertion of the gastric tube, Insertion of the bladder catheter and Skin incision.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Nociception level index (NoI)</measure>
    <time_frame>Between induction and first incision</time_frame>
    <safety_issue>No</safety_issue>
    <description>The NoL measures the magnitude of the autonomic responses to painful stimuli. The NoL combines information from several physiological parameters which represent different autonomic pathways.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular parameters</measure>
    <time_frame>Between induction and first incision</time_frame>
    <safety_issue>No</safety_issue>
    <description>Individual pain related cardiovascular parameters, as heart rate, blood pressure and PPG wave amplitude.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Movement</measure>
    <time_frame>Between induction and first incision</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visible occurence of movement during painfull stimuli.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of anesthesia</measure>
    <time_frame>Between induction and first incision</time_frame>
    <safety_issue>No</safety_issue>
    <description>Depth of anesthesia is measured by a Bispectral Index monitor. Changes in depth of anesthesia will be recorded during painfull stimuli</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>PROPOFOL ONLY GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study group measurements will be obtained before intubation or opioid administration. To that end plasma propofol concentration will be increased slowly from 0 to 4 μg/ml in steps of 0.5 μg/mL. After the highest target is reached, the propofol target concentration will be lowered to get a BIS value of 50. After 5-min, the laryngoscope will be inserted into the mouth. Next the laryngoscope will be removed. After 5-min the laryngoscope will be placed again and the patient will be intubated.  This will be done without additional administration of muscle relaxant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 1 ng/ml remifentanil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 2 ng/ml remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 3 ng/ml remifentanil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 5 ng/ml remifentanil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS 70.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)</description>
    <arm_group_label>PROPOFOL ONLY GROUP</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET A</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET B</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET C</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET D</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET E</arm_group_label>
    <arm_group_label>PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C</arm_group_label>
    <arm_group_label>PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)</description>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET A</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET B</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET C</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET D</arm_group_label>
    <arm_group_label>PROPOFOL + REMIFENTANIL TARGET E</arm_group_label>
    <arm_group_label>PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C</arm_group_label>
    <arm_group_label>PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18‐80 years;

          -  Sex: male or female;

          -  Surgery: Any surgery under general anesthesia;

          -  ASA status: 1, 2 or 3.

        Exclusion Criteria:

          -  Age: &lt; 18 or &gt; 80 years;

          -  Unable to give written informed consent;

          -  Pregnancy/lactation;

          -  Extreme obesity: BMI &gt; 35;

          -  Perceived difficult intubation.

          -  Patients requiring a rapid sequence induction

          -  Patients on beta‐blockers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Dahan, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albert Dahan, MD, PhD, Professor</last_name>
    <phone>+31 71 52 62301</phone>
    <email>a.dahan@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Albert Dahan, MD, PhD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Treister R, Kliger M, Zuckerman G, Goor Aryeh I, Eisenberg E. Differentiating between heat pain intensities: the combined effect of multiple autonomic parameters. Pain. 2012 Sep;153(9):1807-14. doi: 10.1016/j.pain.2012.04.008. Epub 2012 May 29.</citation>
    <PMID>22647429</PMID>
  </reference>
  <reference>
    <citation>Ben-Israel N, Kliger M, Zuckerman G, Katz Y, Edry R. Monitoring the nociception level: a multi-parameter approach. J Clin Monit Comput. 2013 Jul 9. [Epub ahead of print]</citation>
    <PMID>23835792</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>July 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nociception</keyword>
  <keyword>General anesthesia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
